Rion
RION is a clinical-stage regenerative medicine company based in Rochester, MN, dedicated to revolutionizing exosome science to heal from within. Founded in 2017 out of the Mayo Clinic Employee Entrepreneurial Program, the company focuses on harnessing the power of platelet-derived exosomes, particularly through their proprietary Purified Exosome Product (PEP™), to promote tissue regeneration and advance regenerative medicine. RION aims to change the approach to regenerative medicine by utilizing exosome technology to improve patients' lives across various diseases and conditions.
Industries
Nr. of Employees
small (1-50)
Rion
Patents
Microbial particle measuring apparatus and microbial particle measuring method
US-11474017-B2
View Details
Microbial particle measuring apparatus and microbial particle measuring method
US-11474017-B2
View DetailsProducts
Purified platelet-derived exosome product (lyophilized)
A lyophilized platelet-derived extracellular vesicle ingredient intended for therapeutic and research use; vials can be manufactured to contain very high particle counts and are reconstitutable for multiple administration routes.
Purified Exosome Product (PEP)
A novel drug substance containing trillions of platelet-derived regenerative exosomes packaged as a room-temperature stable lyophilized powder.
PEP + Fibrin Gel
Platelet-derived exosome product combined with fibrin gel for advanced wound care and chronic refractory wounds.
cPEP
Canine platelet-derived exosome therapy for veterinary musculoskeletal conditions.
ePEP
Equine platelet-derived exosome therapy for veterinary musculoskeletal injuries.
PEP + saline
Platelet-derived exosome therapeutic formulation using saline for musculoskeletal and medical aesthetics applications.
Purified platelet-derived exosome product (lyophilized)
A lyophilized platelet-derived extracellular vesicle ingredient intended for therapeutic and research use; vials can be manufactured to contain very high particle counts and are reconstitutable for multiple administration routes.
Purified Exosome Product (PEP)
A novel drug substance containing trillions of platelet-derived regenerative exosomes packaged as a room-temperature stable lyophilized powder.
PEP + Fibrin Gel
Platelet-derived exosome product combined with fibrin gel for advanced wound care and chronic refractory wounds.
cPEP
Canine platelet-derived exosome therapy for veterinary musculoskeletal conditions.
ePEP
Equine platelet-derived exosome therapy for veterinary musculoskeletal injuries.
PEP + saline
Platelet-derived exosome therapeutic formulation using saline for musculoskeletal and medical aesthetics applications.
Services
End-to-end production of platelet-derived vesicle drug substance at clinical scale, including isolation, formulation (lyophilization), and stability support.
Platform development to encapsulate or load therapeutic payloads (mRNA, siRNA, DNA, proteins, small molecules) into platelet-derived vesicles for targeted delivery.
Design and conduct of in vivo efficacy and biodistribution studies in rodent and large-animal models across indications including wound healing, musculoskeletal, neural, cardiac, and pulmonary disease.
Development and execution of analytical workflows including particle sizing, TEM, western blot, ELISA, RT-qPCR, flow cytometry, and imaging-based biodistribution assays.
End-to-end production of platelet-derived vesicle drug substance at clinical scale, including isolation, formulation (lyophilization), and stability support.
Platform development to encapsulate or load therapeutic payloads (mRNA, siRNA, DNA, proteins, small molecules) into platelet-derived vesicles for targeted delivery.
Design and conduct of in vivo efficacy and biodistribution studies in rodent and large-animal models across indications including wound healing, musculoskeletal, neural, cardiac, and pulmonary disease.
Development and execution of analytical workflows including particle sizing, TEM, western blot, ELISA, RT-qPCR, flow cytometry, and imaging-based biodistribution assays.
Expertise Areas
- Exosome manufacturing and scale-up
- Exosome-based drug delivery
- Preclinical in vivo studies (rodent and porcine)
- Clinical trial development for biologic therapeutics
Key Technologies
- Platelet-derived extracellular vesicles (exosomes)
- Lyophilization for biologics
- Encapsulation/loading of nucleic acids and small molecules
- Nebulized pulmonary delivery